Zepeski A, Faine B A, Ghannam M, Olalde H M, Wendt L, Naidech A, Mohr N M, Leira E C
medRxiv. 2024 Aug 8:2024.08.07.24311652. doi: 10.1101/2024.08.07.24311652.
Intracranial hemorrhage (ICH) is a serious complication associated with oral anticoagulant use and is associated with significant morbidity and mortality. Although anticoagulation reversal agents are utilized as standard of care, practitioners are limited in their ability to assess degree of anticoagulation reversal for direct oral anticoagulants (DOACs). There is a clinical need identify biomarkers to assess anticoagulation status in patients with DOAC-associated ICH to ensure hemostatic efficacy of anticoagulation reversal agents in the acute setting. The purpose of this study was to assess the utility of thromboelastography (TEG) to assess the impact of anticoagulation reversal in patients presenting to the emergency department (ED) with DOAC-associated ICH.
We conducted a prospective, observational cohort study in adult patients presenting to the ED with acute DOAC-associated ICH. Patients were excluded if last DOAC dose was >48 hours prior to hospital arrival, if they experienced polytrauma, were pregnant, incarcerated, had a history of hepatic failure or coagulopathy, or received anticoagulation reversal with products other than prothrombin complex concentrates (PCCs). We collected baseline TEG samples from participants prior to anticoagulation reversal, as well as 30-minutes, 12-hours, and 24-hours post-reversal. TEG samples were also collected from participants who transferred to our facility after reversal at ED presentation, as well as 12- and 24-hours post-reversal.
Pre-reversal TEG was collected on 10 participants prior to DOAC reversal. A significant decrease in TEG R-time was observed at 30 minutes post-reversal. R-time increased at 12- and 24-hours to baseline levels. Significant changes were not observed in K-time, clot strength, maximum amplitude, or coagulation index.
TEG R-time may be able to detect a change in anticoagulation activity of DOACs in ICH after anticoagulation reversal. R-time decreases acutely after anticoagulation reversal and rebounds at 12- and 24-hours post-reversal.
颅内出血(ICH)是口服抗凝剂使用相关的严重并发症,与显著的发病率和死亡率相关。尽管抗凝逆转剂被用作标准治疗方法,但从业者评估直接口服抗凝剂(DOACs)抗凝逆转程度的能力有限。临床上需要识别生物标志物,以评估DOAC相关ICH患者的抗凝状态,确保抗凝逆转剂在急性情况下的止血效果。本研究的目的是评估血栓弹力图(TEG)在评估因DOAC相关ICH就诊于急诊科(ED)的患者中抗凝逆转影响的效用。
我们对因急性DOAC相关ICH就诊于ED的成年患者进行了一项前瞻性观察队列研究。如果最后一次DOAC剂量在入院前>48小时、经历多发伤、怀孕、被监禁、有肝衰竭或凝血病病史,或接受除凝血酶原复合物浓缩物(PCCs)以外的产品进行抗凝逆转,则排除患者。我们在抗凝逆转前、逆转后30分钟、12小时和24小时从参与者收集基线TEG样本。对于在ED就诊时逆转后转入我们机构的参与者,以及逆转后12小时和24小时,也收集了TEG样本。
在10名参与者进行DOAC逆转之前收集了逆转前TEG。逆转后30分钟观察到TEG R时间显著缩短。R时间在12小时和24小时增加至基线水平。在K时间、血凝块强度、最大振幅或凝血指数方面未观察到显著变化。
TEG R时间可能能够检测ICH患者抗凝逆转后DOAC抗凝活性的变化。抗凝逆转后R时间急性缩短,并在逆转后12小时和24小时反弹。